Cargando…

The effect of prior cancer on non‐small cell lung cancer trial eligibility

OBJECTIVES: Approximately 20% of patients diagnosed with non‐small cell lung cancer (NSCLC) have a history of prior (non‐lung) cancer. Patients with prior cancer are frequently excluded from clinical trials. We aimed to assess the potential impact of prior cancer on commonly used clinical trial endp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herman, Michael, Liu, Zhihui, Shepherd, Frances A., Leighl, Natasha, Liu, Geoffrey, Bradbury, Penelope A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290254/ https://www.ncbi.nlm.nih.gov/pubmed/34145985 http://dx.doi.org/10.1002/cam4.4049

Ejemplares similares

Real‐world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non‐small cell lung cancer
por: Jiang, Shirley Xue, et al.
Publicado: (2019)

Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancer
por: Sung, Mike, et al.
Publicado: (2020)

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021)

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
por: Leighl, Natasha B., et al.
Publicado: (2017)

Sponsorship of oncology clinical trials in the United States according to age of eligibility
por: Neel, Dylan V., et al.
Publicado: (2020)

Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
por: Kuang, Shelley, et al.
Publicado: (2022)

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials
por: Ferrarotto, Renata, et al.
Publicado: (2021)

Neurological Death is Common in Patients With EGFR Mutant Non-Small Cell Lung Cancer Diagnosed With Brain Metastases
por: Ramotar, Matthew, et al.
Publicado: (2019)

Barriers to non-small cell lung cancer trial eligibility
por: Hardesty, Jeffrey J., et al.
Publicado: (2017)

Differential eligibility of African American and European American lung cancer cases using LDCT screening guidelines
por: Ryan, Bríd M
Publicado: (2016)

The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer
por: Shi, Xiaoshun, et al.
Publicado: (2019)

Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
por: Jahanzeb, Mohammad, et al.
Publicado: (2022)

Tumor suppressor properties of the small C-terminal domain phosphatases in non-small cell lung cancer
por: Krasnov, George S., et al.
Publicado: (2019)

Metabolites as Prognostic Markers for Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Platinum-Doublet Chemotherapy
por: Hao, Desirée, et al.
Publicado: (2020)

Trends in phase III randomized controlled clinical trials on the treatment of advanced non‐small‐cell lung cancer
por: Fernández‐López, Cristina, et al.
Publicado: (2016)

Impact of prior malignancies on outcome of colorectal cancer; revisiting clinical trial eligibility criteria
por: Al-Husseini, Muneer J., et al.
Publicado: (2019)

Perspectives of Screening‐Eligible Women and Male Partners on Benefits of and Barriers to Treatment for Precancerous Lesions and Cervical Cancer in Kenya
por: Ragan, Kathleen R., et al.
Publicado: (2017)

EGFR‐mutated stage IV non‐small cell lung cancer: What is the role of radiotherapy combined with TKI?
por: Liu, Bailong, et al.
Publicado: (2021)

Emerging therapies for non-small cell lung cancer
por: Zhang, Chao, et al.
Publicado: (2019)

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
por: Ala‐Leppilampi, Kari, et al.
Publicado: (2020)

Enhancing treatment decision-making: pilot study of a treatment decision aid in stage IV non-small cell lung cancer
por: Leighl, N B, et al.
Publicado: (2008)

The relationship between chronic obstructive pulmonary disease and non‐small cell lung cancer in the elderly
por: Wang, Peng, et al.
Publicado: (2019)

Impact of somatic mutations on prognosis in resected non‐small‐cell lung cancer: The Japan Molecular Epidemiology for lung cancer study
por: Tamiya, Akihiro, et al.
Publicado: (2020)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Lung cancer in never smokers from the Princess Margaret Cancer Centre
por: Korpanty, Grzegorz J., et al.
Publicado: (2018)

Anlotinib for patients with small cell lung cancer and baseline liver metastases: A post hoc analysis of the ALTER 1202 trial
por: Cheng, Ying, et al.
Publicado: (2021)

Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria
por: Sun, Xuqi, et al.
Publicado: (2021)

Serum RNAs can predict lung cancer up to 10 years prior to diagnosis
por: Umu, Sinan U, et al.
Publicado: (2022)

Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer
por: Yan, Peng, et al.
Publicado: (2021)

A new scoring system for predicting survival in patients with non-small cell lung cancer
por: Schild, Steven E, et al.
Publicado: (2015)

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients
por: Kim, Lucia, et al.
Publicado: (2017)

Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine
por: Soldera, Sara Victoria, et al.
Publicado: (2017)

The roles of MASPIN expression and subcellular localization in non-small cell lung cancer
por: Wang, Xiao-Fei, et al.
Publicado: (2020)

Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer
por: Puri, Sonam, et al.
Publicado: (2020)

Clinicopathological and prognostic value of S100A4 expression in non-small cell lung cancer: a meta-analysis
por: Zhang, Jing, et al.
Publicado: (2020)

Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
por: Sung, Mike R., et al.
Publicado: (2021)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer
por: Bhateja, Priyanka, et al.
Publicado: (2019)

Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy
por: Garcia-Pardo, Miguel, et al.
Publicado: (2022)

Nanoparticle albumin‐bound paclitaxel in elder patients with advanced squamous non‐small‐cell lung cancer: A retrospective study
por: Liu, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_epnmab6ou3658ei67c0f4m1lpe